Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 4/20 | 0.56 |
| ▸ | MMP12 | P39900 | 4/20 | 0.56 |
| ▸ | MMP13 | P45452 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197649 | 0.87 | NPC1 (0.57) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL4174812 | 0.83 | MMP8 (0.75) | MMP8MMP12MMP13NPC1RAB9A | |
| SCHEMBL4170793 | 0.80 | MMP12 (0.82) | MMP8MMP12MMP13MMP1MMP7 | |
| SCHEMBL4620668 | 0.80 | AKR1C3 (0.48) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL4622370 | 0.80 | AKR1C3 (0.48) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL4620658 | 0.80 | AKR1C3 (0.48) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL4620988 | 0.78 | AKR1C3 (0.47) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL4621513 | 0.78 | AKR1C3 (0.47) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL4621737 | 0.78 | AKR1C3 (0.47) | NPC1RAB9AAKR1C3MTNR1AMTNR1B | |
| SCHEMBL15895227 | 0.77 | TAAR1 (0.57) | AKR1C3MTNR1AMTNR1BHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | MMP8 1636/4885MMP12 1873/4885MMP13 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.